Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Potassium iodide goes nuclear

This article was originally published in The Tan Sheet

Executive Summary

State and local governments should make potassium iodide pills available to people age 40 and younger living near nuclear power plants, especially children and pregnant and lactating women, according to a report from the National Academies' Research Council to be published in early 2004. Distribution and Administration of Potassium Iodide in the Event of a Nuclear Incident also calls on the federal government to provide financial support to states to help implement distribution plans and keep back-up stores. Research Council asks FDA to extend allowable shelf life for tablets being stored for an emergency. Although the pill can protect against thyroid cancer after an incident, it "will not protect the body against other types of radioactive isotopes released during nuclear reactor incidents or those likely to be used in a so-called dirty bomb," authors note...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096251

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel